Brain metastases are one of the most common neurologic complications of cancer. The
incidence is 9%–17% based on various studies, although the exact incidence is thought to …

The advent of HER2-directed therapies has significantly improved the outlook for patients
with HER2-positive early stage breast cancer. However, a significant proportion of these …

This review examines the relationship between physical activity and cancer along the
cancer continuum, and serves as a synthesis of systematic and meta-analytic reviews …

Objectives: The purpose of this study was to estimate heart failure (HF) and cardiomyopathy
(CM) rates after adjuvant trastuzumab therapy and chemotherapy in a population of older …

Purpose Lapatinib, a small molecule EGFR/HER2 inhibitor, partially inhibits the outgrowth of
HER2+ brain metastases in preclinical models and in a subset of CNS lesions in clinical …

In vivo studies of the metastatic process are severely hampered by the fact that most human
tumor cell lines derived from highly metastatic tumors fail to consistently metastasize in …

The success of endocrine therapies for hormone receptor‐positive breast cancer and
trastuzumab and lapatinib for targeting human epidermal growth factor receptor 2 (HER2) …

Objective Recent studies in breast cancer patients and Trastuzumab therapy (Herceptin)
showed a development of a toxic cardiomyopathy as a severe complication. The aim of this …

Introduction: Large randomized trials assessing the benefit of adjuvant trastuzumab in early-
stage breast cancer positive for the human epidermal growth factor receptor 2 (her 2) have …

It is important to weigh both the risk of CVD and that of breast cancer recurrence in a breast
cancer survivor. Certain interventions for the primary prevention of CVD, including diet …